Literature DB >> 23685409

Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.

Federica Ruffini1, Stefania D'Atri, Pedro M Lacal.   

Abstract

The majority of human melanoma cell lines secretes vascular endothelial growth factor-A (VEGF-A) and expresses its receptors VEGFR-1, VEGFR-2 and neuropilin-1 (NRP‑1), a co-receptor for VEGF-A that amplifies the signalling through VEGFR-2. Since it is known that the VEGF-A/VEGFR-2 autocrine loop promotes melanoma cell invasiveness, the aim of the present study was to investigate the involvement of NPR-1 in melanoma progression. Syngeneic human melanoma cell lines expressing either VEGFR-2 or NRP-1, both or none of them, were analyzed for their in vitro ability to migrate, invade the extracellular matrix (ECM) and secrete active metalloproteinase-2 (MMP-2). The results indicate that NRP-1 cooperates with VEGFR-2 in melanoma cell migration induced by VEGF-A. Moreover, NRP-1 expression is sufficient to promote MMP-2 secretion and melanoma cell invasiveness, as demonstrated by the ability of cells expressing solely NRP-1 to spontaneously invade the ECM. This ability is specifically downregulated by anti-NRP-1 antibodies or by interfering with NRP-1 expression using an shRNA construct. Investigation of the signal transduction pathways triggered by NRP-1 in melanoma cells, indicated that NRP-1-dependent promotion of cell invasiveness involves Akt activation through its phosphorylation on T308. Overall, the results demonstrate that NRP-1 is involved in melanoma progression through VEGFR-2-dependent and -independent mechanisms and suggest NRP-1 as a target for the treatment of the metastatic disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685409     DOI: 10.3892/ijo.2013.1948

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

Review 1.  Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction.

Authors:  Courtney K Domigan; Safiyyah Ziyad; M Luisa Iruela-Arispe
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-10-02       Impact factor: 8.311

2.  BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.

Authors:  Tao Wang; Min Xiao; Yingbin Ge; Clemens Krepler; Eric Belser; Alfonso Lopez-Coral; Xiaowei Xu; Gao Zhang; Rikka Azuma; Qin Liu; Rui Liu; Ling Li; Ravi K Amaravadi; Wei Xu; Giorgos Karakousis; Tara C Gangadhar; Lynn M Schuchter; Melissa Lieu; Sanika Khare; Molly B Halloran; Meenhard Herlyn; Russel E Kaufman
Journal:  Clin Cancer Res       Date:  2015-01-23       Impact factor: 12.531

3.  Use of Labelled tLyP-1 as a Novel Ligand Targeting the NRP Receptor to Image Glioma.

Authors:  Hu-bing Wu; Zhen Wang; Quan-shi Wang; Yan-jian Han; Meng Wang; Wen-lan Zhou; Hong-sheng Li
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

4.  Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.

Authors:  Tao Ji; Yi Guo; Kapjun Kim; Peter McQueen; Samia Ghaffar; Alexander Christ; Carol Lin; Ramez Eskander; Xiaolin Zi; Bang H Hoang
Journal:  Mol Cancer       Date:  2015-04-17       Impact factor: 27.401

Review 5.  Neuropilin-1 as Therapeutic Target for Malignant Melanoma.

Authors:  Grazia Graziani; Pedro M Lacal
Journal:  Front Oncol       Date:  2015-06-03       Impact factor: 6.244

6.  Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.

Authors:  Claudia Ceci; Lucio Tentori; Maria Grazia Atzori; Pedro M Lacal; Elena Bonanno; Manuel Scimeca; Rosella Cicconi; Maurizio Mattei; Maria Gabriella de Martino; Giuseppe Vespasiani; Roberto Miano; Grazia Graziani
Journal:  Nutrients       Date:  2016-11-22       Impact factor: 5.717

7.  Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.

Authors:  Jing Lu; Yabin Cheng; Guohong Zhang; Yun Tang; Ziming Dong; Kevin J McElwee; Gang Li
Journal:  Mol Med Rep       Date:  2015-05-07       Impact factor: 2.952

8.  MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression.

Authors:  Yang Peng; Yan-Min Liu; Lu-Chun Li; Lu-Lu Wang; Xiao-Ling Wu
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

9.  Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib.

Authors:  Simona Caporali; Ester Alvino; Pedro Miguel Lacal; Federica Ruffini; Lauretta Levati; Laura Bonmassar; Alessandro Scoppola; Paolo Marchetti; Simona Mastroeni; Gian Carlo Antonini Cappellini; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-12-09

Review 10.  Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.

Authors:  Ana Cavaco; Maryam Rezaei; Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.